Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
Authors
Kaushal Desai
Merck & Co., Inc., Rahway, NJ
Kaushal Desai , Sneha Sura , Zhimei Liu , Mayur Amonkar , Rishi Jain , Nicole Niehoff , Thomas W Wilson , Gregory A. Patton , David Cosgrove
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 53)
DOI
10.1200/JCO.2024.42.3_suppl.53
Abstract #
53
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
First Author: Seiichiro Mitani
Poster
2019 Gastrointestinal Cancers Symposium
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
First Author: Yoshito Komatsu
Poster
2018 ASCO Annual Meeting
REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.
First Author: Yasushi Tsuji
Poster
2018 Gastrointestinal Cancers Symposium
Metastatic colorectal cancer (mCRC) treatment patterns in the Medicare population.
First Author: Jeremy Snider